Literature DB >> 2442553

Evaluation of antihypertensive efficacy of lisinopril compared to metoprolol in moderate to severe hypertension.

P K Zachariah, G Bonnet, S G Chrysant, G DeBacker, R Goldstein, J Herrera, A Lindner, B J Materson, M H Maxwell, F G McMahon.   

Abstract

A double-blind controlled, randomized, parallel, multicenter 12-week study was conducted to compare the antihypertensive efficacy of lisinopril with that of metoprolol in treatment of moderate to severe hypertension. Initially, 118 patients were recruited on lisinopril and 61 on metoprolol; and for the purpose of efficacy analysis at week 8, 115 patients on lisinopril and 60 on metoprolol were included. The doses of lisinopril or metoprolol were 40-80 mg/day and 100-200 mg/day, respectively. At week 4, the pretreatment diastolic blood pressure of 111 mm Hg was decreased to 97 mm Hg (p less than 0.01) with lisinopril: metoprolol decreased the diastolic blood pressure from 110 to 99 mm Hg (p less than 0.01). Similar decreases were noted at week 8; however, the drop in blood pressure with lisinopril was not significantly different from that with metoprolol. Systolic blood pressure also demonstrated a decrease of about 18 mm Hg with lisinopril and 12 mm Hg with metoprolol (p less than 0.01). This larger decrease in systolic blood pressure with lisinopril was statistically significant at week 4 (p less than 0.05). These decreases in systolic blood pressures were maintained at week 8, again with statistical significance (p less than 0.01). Of the 118 lisinopril-treated patients, four were discontinued from lisinopril therapy because of headache, dizziness, rash, flushing, or lymphadenopathy. Four patients out of 61 (9.8%) were discontinued from metoprolol therapy because of fatigue, somnolence, asthenia, weight gain, flatulence, tremor, or bronchospasm. In conclusion, lisinopril 40-80 mg once daily is as effective as metoprolol 100-200 mg once daily in reducing diastolic blood pressure in patients with moderate to severe hypertension.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2442553     DOI: 10.1097/00005344-198700003-00013

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

Review 1.  Safety profiles of the angiotensin-converting enzyme inhibitors.

Authors:  N J Warner; J E Rush
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 2.  Angiotensin converting enzyme inhibitors and moderate hypertension.

Authors:  D McAreavey; J I Robertson
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

3.  Lisinopril: dose-peak effect relationship in essential hypertension.

Authors:  V J Cirillo; H J Gomez; J Salonen; R Salonen; V Rissanen; J A Bolognese; R Nyberg; K Kristianson
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335

Review 4.  Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  S G Lancaster; P A Todd
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

5.  Lisinopril in elderly patients with hypertension. Long term effects on renal and metabolic function.

Authors:  M S Laher
Journal:  Drugs       Date:  1990       Impact factor: 9.546

6.  Lisinopril dose-response relationship in essential hypertension.

Authors:  H J Gomez; V J Cirillo; J A Sromovsky; E S Otterbein; W C Shaw; J E Rush; S G Chrysant; A H Gradman; A S Leon; E P MacCarthy
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

Review 7.  Current and future status of beta-blockers in the treatment of hypertension.

Authors:  Steven G Chrysant; George S Chrysant; Billy Dimas
Journal:  Clin Cardiol       Date:  2008-06       Impact factor: 2.882

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.